Breaking barriers: Neprilysin inhibition in chronic cardiorenal syndrome

doi:10.4330/wjc.v17.i7.107539

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (150)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

HTML

Tables (1-1)

Sum=129

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=12

Jul 26, 2025 (publication date) through Jul 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Cardiol. Jul 26, 2025; 17(7): 107539
Published online Jul 26, 2025. doi: 10.4330/wjc.v17.i7.107539

Breaking barriers: Neprilysin inhibition in chronic cardiorenal syndrome

Olesya Ilkun, Amir Kazory

Olesya Ilkun, Amir Kazory, Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL 32610, United States

Author contributions: Both Ilkun O and Kazory A searched the literature, designed, wrote, edited, and revised the manuscript; Kazory A submitted the manuscript.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Amir Kazory, Professor, Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, 1600 Sw Archer Rd Box 100224, Gainesville, FL 32610, United States. amir.kazory@medicine.ufl.edu

Received: March 26, 2025
Revised: April 29, 2025
Accepted: June 16, 2025
Published online: July 26, 2025
Processing time: 119 Days and 0.3 Hours

Core Tip

Core Tip: Patients with advanced chronic kidney disease and end-stage kidney disease face disproportionally high rates of heart failure and mortality. Currently, there is an unmet need for medical therapies for heart failure in these populations. This review summarizes information regarding the safety and efficacy of the use of angiotensin receptor/neprilysin inhibition in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease or end-stage kidney disease to help guide safe clinical management.